Page 37 - Haematologica Vol. 107 - September 2022

REVIEW ARTICLE - ITP: diagnosis and second-line treatment J.B. Bussel and C.A. Garcia
romiplostim use connected to pregnancy. Blood.
2021;138(Suppl 1):585.
75. Zhang H, Zhang BM, Guo X, et al. Blood transcriptome and
clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. Haematologica. 2020;105(3):e129-e132.
76. Ogawa S. Genetics of MDS. Blood. 2019;133(10):1049-1059.
77. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The
bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630-1638.
78. Tsuda H, Tsuji T, Tsuji M, Yamasaki H. Life-threatening bleeding episodes in primary immune thrombocytopenia: a single-center retrospective study of 169 inpatients. Ann Hematol. 2017;96(11):1915-1920.
79. Sokal A, de Nadai T, Maquet J, et al. Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France Registry. Br J Haematol. 2022;196(5):1262-1270.
80. Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84(10):661-665.
81. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623-2634.
82. Mahevas M, Guillet S, Viallard J-F, et al. Rate of prolonged response after stopping thrombopoietin-receptor agonists treatment in primary immune thrombocytopenia (ITP): results from a nationwide prospective multicenter interventional study (STOPAGO). Blood. 2021;138(Suppl 1):583.
83. Vianelli N, Auteri G, Buccisano F, et al. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol. 2022;101(5):963-978.
84. Newland AC, Sanchez-Gonzalez B, Rejto L, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95(2):178-187.
85. Robak T, Kazmierczak M, Jarque I, et al. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv. 2020;4(17):4136-4146.
86. Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med. 2022;386(15):1421-1431.
87. Varley CD, Winthrop KL. Long-term safety of rituximab (risks of viral and opportunistic infections). Curr Rheumatol Rep. 2021;23(9):74.
88. Rodeghiero F, Cantoni S, Carli G, et a. Practical recommendations for the management of patients with ITP during the COVID-19 pandemic. Mediterr J Hematol Infect Dis. 2021;13(1):e2021032.
89. Lee EJ, Liu X, Hou M, Bussel JB. Immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2021;193(6):1093-1095.
90. Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med. 2005;10(2):149-159.
91. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in- hospital management and birth outcomes. Am J Gastroenterol. 2008;103(5):1203-1209.
92. Anglin BV, Rutherford C, Ramus R, Lieser M, Jones DB. Immune thrombocytopenic purpura during pregnancy: laparoscopic treatment. JSLS. 2001;5(1):63-67.
Haematologica | 107 September 2022
2036